Search tips
Search criteria 


Logo of jclinpathJournal of Clinical PathologyVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
J Clin Pathol. 1999 November; 52(11): 838–841.
PMCID: PMC501597

Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors.


AIM: To investigate the receptor status of the sex steroid hormones in apocrine metaplasia of the breast. METHODS: 82 cases of apocrine metaplasia, including 18 of the rare lesion apocrine adenosis, were studied immunohistochemically for the expression of androgen receptor, oestrogen receptor, and progesterone receptor proteins on formalin fixed, paraffin embedded tissue sections. The standard avidin biotin complex (ABC) technique was followed and appropriate positive and negative controls were used. RESULTS: All the studied cases (82/82) were positive for androgen receptor, but were negative for oestrogen receptor and progesterone receptor. CONCLUSIONS: Apocrine metaplastic epithelium, unlike the normal breast epithelium, is responsive to androgens, through androgen receptors, rather than to the female sex hormones. This may have clinical implications.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (995K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Page DL, Vander Zwaag R, Rogers LW, Williams LT, Walker WE, Hartmann WH. Relation between component parts of fibrocystic disease complex and breast cancer. J Natl Cancer Inst. 1978 Oct;61(4):1055–1063. [PubMed]
  • Tavassoli FA, Norris HJ. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod Pathol. 1994 Oct;7(8):813–818. [PubMed]
  • Roberts MM, Jones V, Elton RA, Fortt RW, Williams S, Gravelle IH. Risk of breast cancer in women with history of benign disease of the breast. Br Med J (Clin Res Ed) 1984 Jan 28;288(6413):275–278. [PMC free article] [PubMed]
  • Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985 Jan 17;312(3):146–151. [PubMed]
  • Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 1996 Jan;5(1):29–32. [PubMed]
  • Wells CA, McGregor IL, Makunura CN, Yeomans P, Davies JD. Apocrine adenosis: a precursor of aggressive breast cancer? J Clin Pathol. 1995 Aug;48(8):737–742. [PMC free article] [PubMed]
  • Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer. 1996 Jun 15;77(12):2529–2537. [PubMed]
  • Wales NA, Ebling FJ. The control of the apocrine glands of the rabbit by steroid hormones. J Endocrinol. 1971 Dec;51(4):763–770. [PubMed]
  • Haagensen DE, Jr, Dilley WG, Mazoujian G, Wells SA., Jr Review of GCDFP-15. An apocrine marker protein. Ann N Y Acad Sci. 1990;586:161–173. [PubMed]
  • Dixon JM, Lumsden AB, Miller WR. The relationship of cyst type to risk factors for breast cancer and the subsequent development of breast cancer in patients with breast cystic disease. Eur J Cancer Clin Oncol. 1985 Sep;21(9):1047–1050. [PubMed]
  • Wellings SR, Alpers CE. Apocrine cystic metaplasia: subgross pathology and prevalence in cancer-associated versus random autopsy breasts. Hum Pathol. 1987 Apr;18(4):381–386. [PubMed]
  • Angeli A, Bradlow HL, Bodian CA, Chasalow FI, Dogliotti L, Haagensen DE., Jr Criteria for classifying breast cyst fluids. Ann N Y Acad Sci. 1990;586:49–52. [PubMed]
  • Ness JC, Sedghinasab M, Moe RE, Tapper D. Identification of multiple proliferative growth factors in breast cyst fluid. Am J Surg. 1993 Sep;166(3):237–243. [PubMed]
  • Bruzzi P, Dogliotti L, Naldoni C, Bucchi L, Costantini M, Cicognani A, Torta M, Buzzi GF, Angeli A. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ. 1997 Mar 29;314(7085):925–928. [PMC free article] [PubMed]
  • Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: a prospective study. Edinburgh Breast Group. Lancet. 1999 May 22;353(9166):1742–1745. [PubMed]
  • Bélanger A, Caron S, Labrie F, Naldoni C, Dogliotti L, Angeli A. Levels of eighteen non-conjugated and conjugated steroids in human breast cyst fluid: relationships with cyst type. Eur J Cancer. 1990 Mar;26(3):277–281. [PubMed]
  • Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. [PubMed]
  • Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol. 1994 Aug;173(4):371–379. [PubMed]
  • Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract. 1997;193(11-12):753–758. [PubMed]
  • Ellis LM, Wittliff JL, Bryant MS, Hogancamp WE, Sitren HS, Bland KI. Correlation of estrogen, progesterone, and androgen receptors in breast cancer. Am J Surg. 1989 Jun;157(6):577–581. [PubMed]
  • Kuenen-Boumeester V, Van der Kwast TH, van Putten WL, Claassen C, van Ooijen B, Henzen-Logmans SC. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int J Cancer. 1992 Oct 21;52(4):581–584. [PubMed]
  • Langer M, Kubista E, Schemper M, Spona J. Androgen receptors, serum androgen levels and survival of breast cancer patients. Arch Gynecol Obstet. 1990;247(4):203–209. [PubMed]
  • Hackenberg R, Hawighorst T, Filmer A, Nia AH, Schulz KD. Medroxyprogesterone acetate inhibits the proliferation of estrogen- and progesterone-receptor negative MFM-223 human mammary cancer cells via the androgen receptor. Breast Cancer Res Treat. 1993;25(3):217–224. [PubMed]
  • Liberato MH, Sonohara S, Brentani MM. Effects of androgens on proliferation and progesterone receptor levels in T47D human breast cancer cells. Tumour Biol. 1993;14(1):38–45. [PubMed]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group